Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$24.78 - $32.48 $217,890 - $285,596
8,793 Added 2283.9%
9,178 $227,000
Q1 2024

Apr 25, 2024

BUY
$32.2 - $42.44 $12,397 - $16,339
385 New
385 $12,000
Q2 2023

Aug 04, 2023

SELL
$37.4 - $44.52 $233,712 - $278,205
-6,249 Reduced 82.18%
1,355 $55,000
Q1 2023

Apr 27, 2023

BUY
$36.5 - $48.0 $277,546 - $364,992
7,604 New
7,604 $293,000
Q2 2022

Aug 03, 2022

SELL
$52.3 - $71.59 $104,286 - $142,750
-1,994 Closed
0 $0
Q1 2022

May 02, 2022

BUY
$51.32 - $68.5 $102,332 - $136,589
1,994 New
1,994 $123,000
Q4 2020

Feb 02, 2021

SELL
$96.85 - $148.25 $526,089 - $805,294
-5,432 Closed
0 $0
Q3 2020

Oct 14, 2020

SELL
$122.47 - $213.56 $1.65 Million - $2.87 Million
-13,451 Reduced 71.23%
5,432 $770,000
Q2 2020

Jul 13, 2020

BUY
$185.52 - $231.25 $903,853 - $1.13 Million
4,872 Added 34.77%
18,883 $3.73 Million
Q1 2020

Apr 29, 2020

BUY
$143.0 - $274.03 $341,913 - $655,205
2,391 Added 20.58%
14,011 $2.75 Million
Q4 2019

Feb 05, 2020

BUY
$146.12 - $215.82 $1.69 Million - $2.5 Million
11,584 Added 32177.78%
11,620 $2.4 Million
Q3 2019

Oct 15, 2019

SELL
$130.44 - $187.64 $1.72 Million - $2.47 Million
-13,173 Reduced 99.73%
36 $5,000
Q2 2019

Jul 26, 2019

BUY
$111.45 - $128.93 $1.47 Million - $1.7 Million
13,209 New
13,209 $1.7 Million
Q1 2019

Apr 18, 2019

SELL
$89.61 - $117.78 $1,612 - $2,120
-18 Closed
0 $0
Q4 2018

Jan 16, 2019

BUY
$87.81 - $110.65 $1,580 - $1,991
18 New
18 $1,000
Q1 2018

Apr 26, 2018

SELL
$94.51 - $120.23 $9,261 - $11,782
-98 Closed
0 $0
Q4 2017

Jan 10, 2018

BUY
$84.48 - $104.02 $8,279 - $10,193
98
98 $9,000

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.76B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.